Asari S, Horikawa M, Tsukamoto H, Kouda K, Hayashi C, Miyai K
Central Laboratory for Clinical Investigation, Osaka University Hospital.
Jpn J Antibiot. 1987 Jul;40(7):1317-31.
Aztreonam (AZT), which has a newly developed and synthetic structure belonging to the group of monobactams, possesses excellent antibacterial activity against a broad range of Gram-negative bacteria (including the beta-lactamase producing strains). Antibacterial activities of AZT were examined and compared with those of 5 antibiotics (cefoperazone (CPZ), latamoxef (LMOX), cefotaxime (CTX), cefmetazole (CMZ) and cefsulodin (CFS) against 296 strains of clinical isolates. The evaluation of antibacterial activities was determined with the inhibition zone diameter obtained by the single disc method. The results can be summarized by three categories as follows: 1. Susceptibility of clinical isolates to AZT and other antibiotics AZT and other 3rd-generation antibiotics (CPZ, LMOX, CTX) showed excellent antibacterial activities against most strains. Especially AZT was more active against Enterobacter cloacae and Serratia marcescens than reference drugs. Against Pseudomonas aeruginosa, the activity of AZT was similar to that of CFS. AZT showed as excellent activity against P. aeruginosa as CFS. 2. Susceptibility of strains isolated from different clinical materials and different clinics AZT showed the highest antibacterial activity against the clinical isolates from sputum, pharynx, urine, pus, bile, puncture fluid, blood and others. AZT exhibited the most potent activity against isolates in the 7 clinics we tested. 3. Susceptibility of strains isolated from inpatients and outpatients AZT demonstrated the highest antibacterial activity (the rate of susceptibility: 87.0%) against strains obtained from inpatients (except for P. aeruginosa). The activity of AZT (81.4%) against P. aeruginosa was as active as that of CFS (81.4%), and it was the highest in all drugs. Antibacterial activity of these antibiotics against bacteria was rated as follows: AZT greater than LMOX greater than CPZ greater than CTX greater than CMZ AZT showed the highest antibacterial activity (100%) against strains isolated in all the materials and at all the clinics tested of outpatients. Antibacterial activity of these antibiotics against isolates from outpatients was rated as follows: AZT greater than CPZ greater than LMOX greater than CTX greater than CMZ.
氨曲南（AZT）是一种新开发的具有合成结构的单环β-内酰胺类抗生素，对多种革兰氏阴性菌（包括产β-内酰胺酶菌株）具有优异的抗菌活性。我们检测了氨曲南的抗菌活性，并与5种抗生素（头孢哌酮（CPZ）、拉氧头孢（LMOX）、头孢噻肟（CTX）、头孢美唑（CMZ）和头孢磺啶（CFS））对296株临床分离菌株的抗菌活性进行了比较。通过单纸片法获得抑菌圈直径来确定抗菌活性的评估。结果可归纳为以下三类：1. 临床分离菌株对氨曲南和其他抗生素的敏感性 氨曲南和其他第三代抗生素（CPZ、LMOX、CTX）对大多数菌株显示出优异的抗菌活性。特别是氨曲南对阴沟肠杆菌和粘质沙雷氏菌的活性比参比药物更强。对于铜绿假单胞菌，氨曲南的活性与头孢磺啶相似。氨曲南对铜绿假单胞菌的活性与头孢磺啶相当。2. 从不同临床材料和不同诊所分离的菌株的敏感性 氨曲南对来自痰液、咽部、尿液、脓液、胆汁、穿刺液、血液等的临床分离菌株显示出最高的抗菌活性。在我们测试的7个诊所中，氨曲南对分离菌株表现出最有效的活性。3. 住院患者和门诊患者分离菌株的敏感性 氨曲南对从住院患者分离的菌株（铜绿假单胞菌除外）显示出最高的抗菌活性（敏感率：87.0%）。氨曲南对铜绿假单胞菌的活性（81.4%）与头孢磺啶（81.4%）相当，且在所有药物中最高。这些抗生素对细菌的抗菌活性评级如下：氨曲南＞拉氧头孢＞头孢哌酮＞头孢噻肟＞头孢美唑 氨曲南对在所有测试材料和所有门诊诊所分离的菌株显示出最高的抗菌活性（100%）。这些抗生素对门诊患者分离菌株的抗菌活性评级如下：氨曲南＞头孢哌酮＞拉氧头孢＞头孢噻肟＞头孢美唑。
